<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01666223</url>
  </required_header>
  <id_info>
    <org_study_id>H-1-2012-049</org_study_id>
    <nct_id>NCT01666223</nct_id>
  </id_info>
  <brief_title>Effect of Bile Acids on GLP-1 Secretion</brief_title>
  <official_title>Effect of Bile Acids in the Gut on GLP-1 Secretion in Healthy Subjects and Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe the physiological, pathophysiological and
      potentially therapeutic implications of bile-induced glucagon-like peptide-1 (GLP-1)
      secretion in human glucose homeostasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesize that even modest increments in endogenous GLP-1 secretion will
      elicit important antidiabetic effects of GLP-1. To evaluate whether bile acids have such
      effects, the investigators plan to perform intraduodenal infusion of two different bile acids
      and placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in GLP-1</measure>
    <time_frame>At baseline, and at 5, 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150 and 180 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in insulin</measure>
    <time_frame>At baseline, and at 5, 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150 and 180 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-peptide</measure>
    <time_frame>At baseline, and at 5, 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150 and 180 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glucagon</measure>
    <time_frame>At baseline, and at 5, 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150 and 180 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glucagon-like-peptide 2 (GLP-2)</measure>
    <time_frame>At baseline, and at 5, 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150 and 180 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glucose-dependent insulinotropic polypeptide (GIP)</measure>
    <time_frame>At baseline, and at 5, 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150 and 180 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in peptide YY (PYY)</measure>
    <time_frame>At baseline, and at 5, 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150 and 180 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in oxyntomodulin</measure>
    <time_frame>At baseline, and at 5, 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150 and 180 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bile acids</measure>
    <time_frame>At baseline, and at 5, 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150 and 180 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gastrin</measure>
    <time_frame>At baseline, and at 5, 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150 and 180 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CCK</measure>
    <time_frame>At baseline, and at 5, 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150 and 180 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in appetite, satiety and prospective food consumption</measure>
    <time_frame>At baseline, and 30, 60, 90, 120 and 180 minutes</time_frame>
    <description>Evaluated by Visual Analog Scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gallbladder volume</measure>
    <time_frame>-30, 0 (baseline), 30, 60, 120 og 180 minutes</time_frame>
    <description>Evaluated by ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in basal metabolic rate</measure>
    <time_frame>At -30, 60 og 150 minutes</time_frame>
    <description>Evaluated by indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bile acid composition</measure>
    <time_frame>At -30, 0, 30, 60, 120 og 180 minutes</time_frame>
    <description>Evaluated by duodenal aspiration</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Colesevelam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chenodeoxycholic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Colesevelam + chenodeoxycholic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colesevelam</intervention_name>
    <description>Colesevelam 3750 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.</description>
    <arm_group_label>Colesevelam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chenodeoxycholic Acid</intervention_name>
    <description>1.250 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.</description>
    <arm_group_label>Chenodeoxycholic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>100 ml saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colesevelam 3750 mg + chenodeoxycholic acid 1250 mg</intervention_name>
    <description>Colesevelam and chenodeoxycholic acid dissolved in 100 ml saline, administered in a duodenal tube at time = 0.</description>
    <arm_group_label>Colesevelam + chenodeoxycholic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients with type 2 diabetes

        Inclusion Criteria:

          -  danish caucasian ethnicity

          -  normal haemoglobin

          -  BMI &gt; 25 kg/m2

          -  HbA1c &lt; 9%

          -  informed consent

        Exclusion Criteria:

          -  liver disease(ALT and AST &gt; upper reference limit)

          -  gastrointestinal disease

          -  liver and biliary tract disease

          -  nephropathy (serum creatinine &gt; 150 μM, and/or albuminuria)

          -  treatment with insulin, glp-1 analogues and/ or DPP-4 inhibitors

          -  treatment with medicine that can not be paused for 12 hours

          -  previous abdominal surgery eg. cholecystectomy

          -  BMI &lt; 18,5 kg/m2 or &gt; 35 kg/m2

        Healthy Volunteers

        Inclusion Criteria:

          -  danish caucasian ethnicity

          -  normal haemoglobin

          -  HbA1c &lt; 6,0 (American Diabetes Association guidelines)

          -  informed consent

        Exclusion Criteria:

          -  liver disease(ALT and AST &gt; upper reference limit)

          -  gastrointestinal disease

          -  liver and biliary tract disease

          -  nephropathy (serum creatinine &gt; 150 μM, and/or albuminuria)

          -  treatment with medicine that can not be paused for 12 hours

          -  previous abdominal surgery eg. cholecystectomy

          -  BMI &lt; 18,5 kg/m2 or &gt; 35 kg/m2

          -  first degree relatives diagnosed with diabetes

          -  previously diagnosed with diabetes, or treated with antidiabetic agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morten Hansen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes Research Division, Department of Internal Medicine, Gentofte Hospital, University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes Research Division, Department of Internal Medicine, Gentofte Hospital, University of Copenhagen</name>
      <address>
        <city>Hellerup</city>
        <state>Copenhagen</state>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, Nakamura T, Itadani H, Tanaka K. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun. 2002 Nov 15;298(5):714-9.</citation>
    <PMID>12419312</PMID>
  </reference>
  <reference>
    <citation>Adrian TE, Ballantyne GH, Longo WE, Bilchik AJ, Graham S, Basson MD, Tierney RP, Modlin IM. Deoxycholate is an important releaser of peptide YY and enteroglucagon from the human colon. Gut. 1993 Sep;34(9):1219-24.</citation>
    <PMID>8406158</PMID>
  </reference>
  <reference>
    <citation>Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun. 2005 Apr 1;329(1):386-90.</citation>
    <PMID>15721318</PMID>
  </reference>
  <reference>
    <citation>Rafferty EP, Wylie AR, Hand KH, Elliott CE, Grieve DJ, Green BD. Investigating the effects of physiological bile acids on GLP-1 secretion and glucose tolerance in normal and GLP-1R(-/-) mice. Biol Chem. 2011 Apr;392(6):539-46. doi: 10.1515/BC.2011.050. Epub 2011 Apr 27.</citation>
    <PMID>21521075</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2012</study_first_submitted>
  <study_first_submitted_qc>August 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2012</study_first_posted>
  <last_update_submitted>December 21, 2013</last_update_submitted>
  <last_update_submitted_qc>December 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Morten Hansen</investigator_full_name>
    <investigator_title>MD, PhD Student</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>GLP-1</keyword>
  <keyword>Bile acid</keyword>
  <keyword>TGR-5</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colesevelam Hydrochloride</mesh_term>
    <mesh_term>Bile Acids and Salts</mesh_term>
    <mesh_term>Chenodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

